Peer Review History

Original SubmissionMay 19, 2020
Decision Letter - Robert Jeenchen Chen, Editor

PONE-D-20-14421

Feasibility and technique of endovenous laser ablation (EVLA) of recurrent varicose veins deriving from the sapheno-femoral junction – a case series of 35 consecutive procedures

PLOS ONE

Dear Dr. Müller,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

Please address the reviewer's concerns and make revisions accordingly. 

==============================

Please submit your revised manuscript by Jul 25 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Robert Jeenchen Chen, MD, MPH

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study. Specifically, please ensure that you have discussed whether all data were fully anonymized before you accessed them.

3. To comply with PLOS ONE submission guidelines, in your Methods section, please provide additional information regarding your statistical analyses. For more information on PLOS ONE's expectations for statistical reporting, please see https://journals.plos.org/plosone/s/submission-guidelines.#loc-statistical-reporting.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The presenting study is a case series.

(1) Case series (and case reports) per definition do not provide any comparison groups. With the introduction of the subgroup analysis of a relatively small number of cases, the reader might confuse the design with the retrospective cohort study (where the control group is present and advisable). I suggest making sure that there is a clear notion about the study design (case series) in the text body - as the authors acknowledged in the title.

(2) The major pitfall for the clinician is to conclude about relationships from case series. The inferences about morbidity cannot be made, based on relatively small numbered case series. I suggest rewriting the conclusion.

The most interesting question raised here would be to address the possible prospective observational study comparing open surgery (OS) to described EVLA technique in terms of morbidity and technical success rate.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Dr. Lars Müller

Department of Vascular Surgery

Dermatologikum Hamburg

Stephansplatz 5

20354 Hamburg

Germany

To

Dr. Robert Jeenchen Chen

Academic Editor

PLOS ONE

1160 Battery Street

Koshland Building East, Suite 225

San Francisco, CA 94111

United States

Hamburg, 15.6.2020

Dear Dr. Chen,

I would like to thank you, also on behalf of my co-author Dr. Alm, for the constructive review process. I also thank the reviewers for their time and effort with our manuscript.

We have revised our manuscript in several respects on the basis of your criticism and suggestions and would now like to explain them to you. For this purpose, we will precede the comments (in bold letters) made by you and by the reviewer and then display our explanations and the respective changes in the manuscript:

Reviewer #1: The presenting study is a case series.

(1) Case series (and case reports) per definition do not provide any comparison groups. With the introduction of the subgroup analysis of a relatively small number of cases, the reader might confuse the design with the retrospective cohort study (where the control group is present and advisable). I suggest making sure that there is a clear notion about the study design (case series) in the text body - as the authors acknowledged in the title.

We agree. We have now referred to the design of the study (case series) at several places in the manuscript. We have also adjusted or scaled down the statements that can be drawn from a case series at several points.

-Abstract: Conclusions Statement (page 3, line 50)

-Introduction: Page 4, line 84

-Discussion: page 15, line 296/297

-Discussion: page 18, line 356 (Observation instead of results)

-Discussion: page 18, line 361

We have also added more specific information to the abstract in order to make it easier to understand what exactly was examined (changes on page 2, lines 28-44)

(2) The major pitfall for the clinician is to conclude about relationships from case series. The inferences about morbidity cannot be made, based on relatively small numbered case series. I suggest rewriting the conclusion.

The most interesting question raised here would be to address the possible prospective observational study comparing open surgery (OS) to described EVLA technique in terms of morbidity and technical success rate.

We can only agree with this comment, and we have immediately adopted this argument in our conclusion (page 18, lines 366-368).

Journal requirements:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

We have revised the names of the image files.

2. In your ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study. Specifically, please ensure that you have discussed whether all data were fully anonymized before you accessed them.

We have reformulated the Ethics Statement, and also the previous chapter Study Population (page 5, lines 94-108)

3. To comply with PLOS ONE submission guidelines, in your Methods section, please provide additional information regarding your statistical analyses.

The chapter on statistics (page 9, line 194 - page 10, line 213) has been rewritten and the text has been changed accordingly:

-Page 10, line 224: Median and Range instead of Average and Standard Deviation.

-Table 1: Median and range is presented for all data which is not normally distributed.

-Page 15, line 289-290: The median follow-up time is now given instead of the average.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly.

This caption at the end of the manuscript was included.

Other small changes that should improve the understanding of the text from our point of view:

-Page 4, line 76

-page 6, line 120-121

-Page 7, line 151

-Page 7, line 160

-The chapter endpoints slightly shortened and rearranged (page 8. lines 178-184)

-Page 13, line 236

-Page 15, line 302

-page 17, line 340, 341

-Supplemental data table (S1_Table): Some corrections have been made to the column labels.

I look forward to hearing from you regarding our submission. We will be happy to continue to answer any further suggestions or queries or to make any necessary changes.

Yours sincerely,

Dr. Lars Müller

Decision Letter - Robert Jeenchen Chen, Editor

Feasibility and technique of endovenous laser ablation (EVLA) of recurrent varicose veins deriving from the sapheno-femoral junction – a case series of 35 consecutive procedures

PONE-D-20-14421R1

Dear Dr. Müller,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Robert Jeenchen Chen, MD, MPH

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: All my comments have been addresed. The methodological constrains of the case series have been adequately emphasized.

Reviewer #2: The manuscript is now acceptable for pubblication, the author have adequately addressed reviewer's comments.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: GIOVANNI DE CARIDI

Formally Accepted
Acceptance Letter - Robert Jeenchen Chen, Editor

PONE-D-20-14421R1

Feasibility and technique of endovenous laser ablation (EVLA) of recurrent varicose veins deriving from the sapheno-femoral junction – a case series of 35 consecutive procedures

Dear Dr. Müller:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Robert Jeenchen Chen

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .